mama en mujeres pre y postmenopáusicas. Med Clin (Barc). 2000:115(8): 281-286. 27. Rahman N, Stratton MR. The genetics of breast cancer susceptibillity. Annu Rev Genet 1998;32:95-121.28. Gomez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer. Eur J Cancer 1999;35(6):867-885.29. Col NF, Eckman NH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997; 277: 1140-1147.30. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density: the Rancho Bernardo Study. JAMA 1997: 277:543-547.31. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomised clinical trial. JAMA 1999;282(7):637-645.32. Beresford SA, Weiss NS, Woigt LF, McNight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-461.33. Hosking D, Clair ED, Chilvers ED et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338:485-492.34. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443.35. Brian WW, Lewis HK, Robert AW et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA;279:1445-145136. Ingran D, Sanders K, Kolibaba M, Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997; 350:990-994.
